Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Carpenter Technology Hikes Base Prices On Specialty Alloy Portfolio

Carpenter Technology Corp (NYSE:CRS) will increase its base prices by an average of 12% to 15% on new, non-contract orders across…
byAkanksha Bakshi
July 6, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Carpenter Technology Corp (NYSE:CRS) will increase its base prices by an average of 12% to 15% on new, non-contract orders across most premium products.
  • The price increases will apply to new orders placed after July 5, 2022. All relevant surcharges will be retained.
  • Price Action: CRS shares are trading lower by 2.68% at $25.41 on the last check Wednesday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Novartis Announced Investigational Oral Monotherapy Iptacopan Demonstrates Clinically Meaningful Superiority over Anti-C5 Treatment in Phase III APPLY-PNH sStudy

By Charles Gross
October 24, 5:09 AM
Novartis today announced the pivotal Phase III APPLY-PNH trial met its two primary endpoints, showing investigational oral monotherapy iptacopan was superior to anti-C5 therapies (eculizumab or ravulizumab) in adults with paroxysmal nocturnal hemoglobinuria (PNH) experiencing residual anemia despite prior treatment with anti-C5s1.

NVS